Brief Reviews |
From the Translational and Molecular Imaging Institute, Mount Sinai School of Medicine, New York.
Correspondence to Zahi A. Fayad, PhD, FAHA, FACC, Mount Sinai School of Medicine, Translational and Molecular Imaging Institute, One Gustave L. Levy Place, Box 1234, New York, NY 10029. E-mail Zahi.Fayad@mssm.edu
Series Editor: Zahi Fayad
Molecular Imaging of Cardiovascular Disease
ATVB In Focus
Articles in this series:
Choudhury RP, Fisher EA. Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol. 2009;29:983–991.
Cormode DP, Skajaa T, Fayad ZA, Mulder WJM. Nanotechnology in medical imaging: probe design and applications. Arterioscler Thromb Vasc Biol. 2009;29:992–1000.
Tang TY, Muller KH, Graves MJ, Li ZY, Walsh SR, Young V, Sadat U, Howarth SPS, Gillard JH. Iron oxide particles for atheroma imaging. Arterioscler Thromb Vasc Biol. 2009;29:1001–1008.
Rudd JHF, Hyafil F, Fayad ZA. Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1009–1016.
Jaffer FA, Libby P, Weissleder R. Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1017–1024.
Kraitchman DL, Bulte JWM. In vivo imaging of stem cells and beta cells using direct cell labeling and reporter gene methods. Arterioscler Thromb Vasc Biol. 2009;29:1025–1030.
Laufer EM, Winkens MHM, Narula J, Hofstra L. Imaging of cell death in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1031–1038.
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
Molecular imaging is defined today as the visualization, characterization, and measurement of biological processes at the molecular and cellular levels in humans and other living systems, and molecular imaging agents are probes used to visualize, characterize, and measure biological processes in living system.
Most of us in the cardiovascular imaging field look at the routine use of molecular imaging in cancer research, clinical trials, and medical practice.1 However, recent developments in cardiovascular biology and biochemistry, coupled with remarkable advances in imaging technologies, are beginning now to make molecular imaging a vital preclinical and clinical tool in the field of atherosclerosis, thrombosis, vascular biology, and cardiovascular medicine.2
In this issue of the ATVB, we present a series of concise review articles on in vivo molecular cardiovascular multimodality imaging. These articles present overview of some the opportunities in the areas of atherosclerosis, thrombosis, inflammation, angiogenesis, apoptosis, diabetes, and cellular therapy. The series also covers the challenges that cardiovascular molecular imaging faces to fulfill its promise in the clinical practice.
The series begins with "Molecular Imaging in Atherosclerosis, Thrombosis, and Vascular Inflammation" by Choudhury and Fisher.3 They provide a comparative analysis of the different imaging modalities that have been used. They emphasize how an understanding of the biology of atherosclerosis and its complications can inform optimal design of the different elements of the contrast agents. They address the potential and limitations of current contrast approaches in respect of translation to clinically usable agents and speculate on future applications. Cormode et al4 cover,
This article has been cited by other articles:
![]() |
C. M. Matter, M. Stuber, and M. Nahrendorf Imaging of the unstable plaque: how far have we got? Eur. Heart J., November 1, 2009; 30(21): 2566 - 2574. [Abstract] [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2009 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |